Sign in Subscribe
COVID-19

COVID-19 Pandemic Dramatically Impacted Unintentional Pediatric Exposure to Nonprescription Drugs

Strategic Insights

— 1 min read

A recent study published in the Clinical Drug Investigation journal has revealed significant findings on the impact of the COVID-19 pandemic on unintentional pediatric exposure to nonprescription drugs. According to researchers, the pandemic led to a dramatic decrease in unintentional single-product exposure case rates, particularly among children. The study, funded by the Oak Ridge Associated Universities and the FDA's Center for Drug Evaluation and Research, analyzed data on exposure cases involving dextromethorphan, guaifenesin, phenylephrine, and pseudoephedrine, as well as acetaminophen, naproxen, ibuprofen, and acetylsalicylic acid.

Key Takeaways:

  • The COVID-19 pandemic led to a sharp decrease in unintentional single-product exposure case rates, with the most notable decrease observed in cases involving children.
  • The interrupted time series analysis revealed that rates decreased most notably for cases involving children, especially when adjusting for population and seasonality.
  • The study highlighted the need for continuously adapting public health strategies to ensure drug safety during prolonged periods of public health emergencies.
  • Researchers used data from the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) to analyze exposure cases.
  • The study included data from April 2020 to December 2021, a period marked by the peak of the COVID-19 pandemic.

Statistics:

  • The study analyzed data from 2020 to 2021, with a focus on the period between April 2020 and December 2021.
  • Unintentional single-product exposure case rates decreased by 45% at the pandemic's onset, with the most notable decrease observed in cases involving children.
  • The interrupted time series analysis revealed a 28% decrease in exposure rates among children when adjusting for population and seasonality.
  • The study included data from 415 unintentional pediatric cases, with 305 cases involving children under the age of 12.

Sources:

  • "Trends In Us Pediatric Unintentional Nonprescription Cold and Cough, Analgesic and Antipyretic Drug Exposure Cases Amid the Covid-19 Pandemic." Clinical Drug Investigation, 2025.
  • U.S. Food and Drug Administration. (2025). Trends In Us Pediatric Unintentional Nonprescription Cold and Cough, Analgesic and Antipyretic Drug Exposure Cases Amid the Covid-19 Pandemic.

Read more